Device Trial Radar · NCT04728087
ACCEL Absorbable Hemostat
Last checked: Nov 19, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
216
Planned (sponsor's estimate)
Start
Oct 26, 2021
Primary completion
Nov 30, 2024
Study completion Jan 30, 2025
Sponsor
- Lead sponsor
- Hemostasis, LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 28, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ACCEL® Absorbable Hemostat Powder Clinical IDE Trial is designed as a prospective, multi-center, randomized, non-inferiority, controlled pivotal clinical trial to evaluate the safety and efficacy of the ACCEL® Absorbable Hemostat Powder as compared to gelatin sponge, for achieving hemostasis in subjects undergoing cardiovascular, liver, or soft tissue surgery, when control of oozing to moderate bleeding by standard surgical techniques is ineffective and/or impractical.
Conditions
- Hemostasis
Interventions
ACCEL® Absorbable Hemostat PowderDevice
Up to 2 bellows (10 grams nominal) of ACCEL®
Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01)Device
Up to 12.5 cm x 8.0 cm of Gelfoam® or SURGIFOAM® .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstration of non-inferiorityTime frame: Day 0 / Surgery
- Determination of incidence of SADE and ADETime frame: Through the six (6) week follow-up.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Keck Medical Center of USC
Los Angeles, California · Completed
Saint Luke's Hospital of Kansas City
Kansas City, Missouri · Completed
Washington University in St. Louis
St Louis, Missouri · Recruiting
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.